165 related articles for article (PubMed ID: 10480230)
1. Use of surface plasmon resonance for studies of protein-protein and protein-phospholipid membrane interactions. Application to the binding of factor VIII to von Willebrand factor and to phosphatidylserine-containing membranes.
Saenko E; Sarafanov A; Greco N; Shima M; Loster K; Schwinn H; Josic D
J Chromatogr A; 1999 Aug; 852(1):59-71. PubMed ID: 10480230
[TBL] [Abstract][Full Text] [Related]
2. The acidic region of the factor VIII light chain and the C2 domain together form the high affinity binding site for von willebrand factor.
Saenko EL; Scandella D
J Biol Chem; 1997 Jul; 272(29):18007-14. PubMed ID: 9218428
[TBL] [Abstract][Full Text] [Related]
3. Activation of factor VIII by thrombin increases its affinity for binding to synthetic phospholipid membranes and activated platelets.
Saenko EL; Scandella D; Yakhyaev AV; Greco NJ
J Biol Chem; 1998 Oct; 273(43):27918-26. PubMed ID: 9774404
[TBL] [Abstract][Full Text] [Related]
4. Effect of von Willebrand Factor and its proteolytic fragments on kinetics of interaction between the light and heavy chains of human factor VIII.
Saenko EL; Loster K; Josic D; Sarafanov AG
Thromb Res; 1999 Dec; 96(5):343-54. PubMed ID: 10605949
[TBL] [Abstract][Full Text] [Related]
5. A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine.
Shima M; Scandella D; Yoshioka A; Nakai H; Tanaka I; Kamisue S; Terada S; Fukui H
Thromb Haemost; 1993 Mar; 69(3):240-6. PubMed ID: 7682339
[TBL] [Abstract][Full Text] [Related]
6. Role of activation of the coagulation factor VIII in interaction with vWf, phospholipid, and functioning within the factor Xase complex.
Saenko EL; Shima M; Sarafanov AG
Trends Cardiovasc Med; 1999 Oct; 9(7):185-92. PubMed ID: 10881749
[TBL] [Abstract][Full Text] [Related]
7. A mechanism for inhibition of factor VIII binding to phospholipid by von Willebrand factor.
Saenko EL; Scandella D
J Biol Chem; 1995 Jun; 270(23):13826-33. PubMed ID: 7775440
[TBL] [Abstract][Full Text] [Related]
8. Slowed release of thrombin-cleaved factor VIII from von Willebrand factor by a monoclonal and a human antibody is a novel mechanism for factor VIII inhibition.
Saenko EL; Shima M; Gilbert GE; Scandella D
J Biol Chem; 1996 Nov; 271(44):27424-31. PubMed ID: 8910322
[TBL] [Abstract][Full Text] [Related]
9. A role for the C2 domain of factor VIII in binding to von Willebrand factor.
Saenko EL; Shima M; Rajalakshmi KJ; Scandella D
J Biol Chem; 1994 Apr; 269(15):11601-5. PubMed ID: 7512568
[TBL] [Abstract][Full Text] [Related]
10. Factor VIII C1 domain spikes 2092-2093 and 2158-2159 comprise regions that modulate cofactor function and cellular uptake.
Bloem E; van den Biggelaar M; Wroblewska A; Voorberg J; Faber JH; Kjalke M; Stennicke HR; Mertens K; Meijer AB
J Biol Chem; 2013 Oct; 288(41):29670-9. PubMed ID: 24009077
[TBL] [Abstract][Full Text] [Related]
11. A monoclonal antibody (NMC-VIII/10) to factor VIII light chain recognizing Glu1675-Glu1684 inhibits factor VIII binding to endogenous von Willebrand factor in human umbilical vein endothelial cells.
Shima M; Yoshioka A; Nakajima M; Nakai H; Fukui H
Br J Haematol; 1992 Aug; 81(4):533-8. PubMed ID: 1390241
[TBL] [Abstract][Full Text] [Related]
12. A new method measuring the interaction between von Willebrand factor and coagulation factor VIII.
Karlman M; Holmström M; Wiman B
Thromb Res; 2011 Jan; 127(1):47-50. PubMed ID: 21094987
[TBL] [Abstract][Full Text] [Related]
13. Factor VIII binds to von Willebrand factor via its Mr-80,000 light chain.
Hamer RJ; Koedam JA; Beeser-Visser NH; Bertina RM; Van Mourik JA; Sixma JJ
Eur J Biochem; 1987 Jul; 166(1):37-43. PubMed ID: 3109914
[TBL] [Abstract][Full Text] [Related]
14. Role of factor VIII C2 domain in factor VIII binding to factor Xa.
Nogami K; Shima M; Hosokawa K; Suzuki T; Koide T; Saenko EL; Scandella D; Shibata M; Kamisue S; Tanaka I; Yoshioka A
J Biol Chem; 1999 Oct; 274(43):31000-7. PubMed ID: 10521497
[TBL] [Abstract][Full Text] [Related]
15. The D' domain of von Willebrand factor requires the presence of the D3 domain for optimal factor VIII binding.
Przeradzka MA; Meems H; van der Zwaan C; Ebberink EHTM; van den Biggelaar M; Mertens K; Meijer AB
Biochem J; 2018 Sep; 475(17):2819-2830. PubMed ID: 30111575
[TBL] [Abstract][Full Text] [Related]
16. Anti-heavy-chain monoclonal antibodies directed to the acidic regions of the factor VIII molecule inhibit the binding of factor VIII to phospholipids and von Willebrand factor.
Raut S; Villard S; Grailly S; Gilles JG; Granier C; Saint-Remy JM; Barrowcliffe TW
Thromb Haemost; 2003 Sep; 90(3):385-97. PubMed ID: 12958606
[TBL] [Abstract][Full Text] [Related]
17. Effect of multimerization of human and recombinant von Willebrand factor on platelet aggregation, binding to collagen and binding of coagulation factor VIII.
Fischer BE; Kramer G; Mitterer A; Grillberger L; Reiter M; Mundt W; Dorner F; Eibl J
Thromb Res; 1996 Oct; 84(1):55-66. PubMed ID: 8885147
[TBL] [Abstract][Full Text] [Related]
18. Thermodynamic analysis of the interaction of factor VIII with von Willebrand factor.
Dimitrov JD; Christophe OD; Kang J; Repessé Y; Delignat S; Kaveri SV; Lacroix-Desmazes S
Biochemistry; 2012 May; 51(20):4108-16. PubMed ID: 22559004
[TBL] [Abstract][Full Text] [Related]
19. Factor VIII inhibitor antibodies with C2 domain specificity are less inhibitory to factor VIII complexed with von Willebrand factor.
Suzuki T; Arai M; Amano K; Kagawa K; Fukutake K
Thromb Haemost; 1996 Nov; 76(5):749-54. PubMed ID: 8950785
[TBL] [Abstract][Full Text] [Related]
20. Kinetics of the interaction between anti-FVIII antibodies and FVIII from therapeutic concentrates, with and without von Willebrand factor, assessed by surface plasmon resonance.
Grancha S; Ortiz AM; Marañón C; Hampel K; Moret A; Zimmermann B; Jorquera JI; Aznar JA
Haemophilia; 2012 Nov; 18(6):982-9. PubMed ID: 22646163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
